We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer.
- Authors
Liu, Yijuan; Wu, Ting; Lu, Dong; Zhen, Jiantao; Zhang, Lin
- Abstract
Background: CD44 has recently been reported as a biomarker for pancreatic cancer. However, the predictive value of CD44 in pancreatic cancer remains controversial. Therefore, we performed this meta-analysis to evaluate the association between the expression of CD44 and clinicopathological features, and the outcome of pancreatic cancer patients. Materials and method: A comprehensive literature search was performed using PubMed, Embase, and Chinese National Knowledge Infrastructure. The statistical analysis was conducted using Stata software. Results: A total of nine studies including 583 cases were included in this meta-analysis. The meta-analysis indicated that CD44 overexpression was associated with poor five-year overall survival rate (OR 0.52; 95% CI 0.30, 0.91; P = 0.02), more lymph node invasion (OR 3.14 (positive vs. negative); 95% CI 1.47, 6.73; P = 0.003), more advanced T stage (OR 2.4 (T3,4 vs. T1,2); 95% CI 1.28, 4.52; P = 0.007), and more advanced TNM stage (OR 4.53 (III~IV vs. I~II); 95% CI 1.46, 14.08; P = 0.01). However, CD44 overexpression was not associated with other clinicopathological features, such as tumor size, differentiation, and distance metastasis. Conclusions: The current evidence suggests that CD44 is an efficient prognostic factor in pancreatic cancer.
- Publication
International Journal of Biological Markers, 2018, Vol 33, Issue 3, p308
- ISSN
0393-6155
- Publication type
Article
- DOI
10.1177/1724600817746951